ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

AscellaHealth’s Patient-Focused Approach is Best-in-Class Model for Distribution of Rare Disease Therapies

BERWYN, Pa., July 15, 2025 (GLOBE NEWSWIRE) -- AscellaHealth, a global partner delivering customizable solutions to support the specialty pharmaceutical industry, distinguishes itself as the partner of choice for rare disease pharmaceutical manufacturers, offering a patient-first, customizable model that supports the successful commercialization and distribution of specialty and rare disease therapies. This commitment is showcased in a three-part series of AscellaHealth Podcast Pulse, featuring Donovan Quill, Chief Strategy Officer, AscellaHealth and Charlie Gayer, Chief Commercial Officer, BioCryst Pharmaceuticals, who highlight the value of these adaptable, patient-focused solutions.

“At AscellaHealth, we recognize that a one-size-fits-all approach doesn’t work when distributing therapies for individuals with complex, chronic and rare diseases,” says Bill Oldham, Chairman and President of AscellaHealth. “That’s why our integrated model delivers the best of all worlds: single-source service, personalized patient support and flexible distribution pathways—ensuring optimal access and outcomes. We’re excited to share this podcast with our colleagues and friends across the industry.”

In part one, the experts explore the critical factors influencing the adoption of exclusive distribution models, including:
•        Product characteristics
•        Patient and prescriber profiles
•        Market dynamics
•        Strategic objectives

Parts two and three focus on the advantages of partnering with a sole-source, exclusive distribution partner and dispel the common misconceptions surrounding this model. A deep dive discussion focuses upon the value of this approach to create more meaningful partnerships, increase stability, and streamline processes for life sciences stakeholders.

“Through exclusive and limited distribution strategies that seamlessly scale into broader, open models, AscellaHealth equips manufacturers with comprehensive, end-to-end solutions that evolve alongside their needs,” states Oldham. “Blending operational efficiency, flexibility and personalized care powered by the human touch, this methodology supports every stage of a product’s lifecycle.”

About AscellaHealth LLC

AscellaHealth is a global partner that delivers proven end-to-end solutions to both life sciences and healthcare companies to enhance the quality of life for patients with complex, chronic conditions. A dedicated team gets critical healthcare products from manufacturers to patients while ensuring an efficient flow of funds between payers and pharma. For more information on our services and solutions, visit www.AscellaHealth.com.

This press release was published by a CLEAR® Verified individual.


Media:

Caroline Chambers
CPR Communications
cchambers@cpronline.com
201.641.1911 x 21

Primary Logo

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.